2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines
- 1 August 1993
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 46 (4) , 762-766
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Clinical and preclinical activity of 2′,2′- difluorodeoxycytidine (gemcitabine)Cancer Treatment Reviews, 1993
- Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter platesBritish Journal of Cancer, 1992
- In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridineBritish Journal of Cancer, 1992
- Clinical relevance of biochemical modulation of 5-fluorouracilAnnals of Oncology, 1991
- A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.Journal of Clinical Oncology, 1991
- In vitro antiproliferative and metabolic activity of eight novel 5-fluorinated uracil nucleosidesEuropean Journal of Cancer and Clinical Oncology, 1991
- Metabolism and Action of 2′, 2′ -Difluorodeoxycytidine: Self-Potentiation of Cytotoxicity1991
- Concentration and Time Dependent Growth Inhibition and Metabolism in vitro by 2’,2’-Difluoro-Deoxycytidine (Gemcitabine)1991
- Biochemical modulation of cytosine arabinosidePharmacology & Therapeutics, 1990
- Purine nucleosides as cell-specific modulators of 5-fluorouracil metabolism and cytotoxicityEuropean Journal of Cancer and Clinical Oncology, 1987